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Abstract: Pulmonary drug delivery of ciprofloxacin hydrochloride offers effective local 
antibacterial activity and convenience of easy application. Spray drying is a trustworthy 
technique for the production of ciprofloxacin hydrochloride microparticles. Quality by design 
(QbD), an up-to-date regulatory-based quality management method, was used to predict the 
final quality of the product. According to the QbD-based theoretical preliminary parameter 
ranking and priority classification, dry powder inhalation formulation tests were successfully 
performed in practice. When focusing on the critical parameters, the practical development 
was more effective and was in correlation with our previous findings. Spray drying produced 
spherical microparticles. The dry powder formulations prepared were examined by particle 
size analysis, scanning electron microscopy, Fourier-transform infrared spectroscopy, X-ray 
powder diffraction, differential scanning calorimetry, and in vitro drug release and aerodynamic 
particle size analyses were also performed. These formulations showed an appropriate particle 
size ranging between 2 and 4 μm and displayed an enhanced aerosol performance with fine 
particle fraction up to 80%.
Keywords: antibiotic, carrier-free formulation, quality by design, aerodynamic evaluation, 
dry powder for inhalation
Introduction
Using antibiotics in a pulmonary dosage form dates back to 1948 when Abbot 
Laboratories developed the aerohaler for inhalation containing penicillin G in a powder 
form.1 The most common treatment for bacterial respiratory infections includes the oral 
administration of high doses of single or combined antibiotics, which may be associated 
with severe side effects because of their high systemic bioavailability.2 The ability to 
deliver the therapeutic agents directly to the site of action may improve the therapeutic 
efficacy for many specific diseases of the respiratory tract3 and has numerous advantages 
over other routes of administration. Lung is a highly absorptive tissue with a large 
surface area and a limited proteolytic activity, sufficient capillaries, and rapid absorp-
tion rate and can be targeted by non-invasive methods.4,5 Therefore, direct delivery 
of antibiotics to a lung infection site leads to much higher drug concentrations in the 
pulmonary tissue; thus, it may produce therapeutic effects at smaller doses compared 
to those required by the oral or parenteral routes,6 while it is associated with a reduced 
systemic antibiotic exposure and a reduced risk of toxicity.7
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Ciprofloxacin is a fluoroquinolone antibiotic, a broad-
spectrum synthetic agent. Its main mechanism of action 
is the inhibition of the bacterial enzymes DNA gyrase8 
(topoisomerase II) and topoisomerase IV, thus preventing 
bacterial DNA from uncoiling and duplicating, leading to 
cell death.9 It has potent and effective activity against a wide 
range of Gram-positive bacteria like Staphylococcus and 
Bacillus species and against most Gram-negative microor-
ganisms like Pseudomonas species, and it is often used in the 
treatment of inhalation anthrax and other lung infections.10 
Current routes of fluoroquinolone administration include 
oral, injection, and ocular deliveries, so its formulation as 
a dry powder inhaler could offer a new possibility of direct 
pulmonary delivery.10 The dry powder inhalation (DPI) 
formulation is a dosage form containing micronized drug 
particles that are small enough to be deposited in the lungs.11 
For local respiratory drug delivery, a particle size of 2–5 μm 
is of the highest benefit.12 A DPI of ciprofloxacin for the 
treatment of lung infections would be well tolerated and 
would also minimize the risk for systemic intolerabilities 
due to minimal systemic exposure.13 Clinical investigations 
show that inhaled antibiotics can decrease the burden and 
delay the onset of superinfections caused by Gram-negative 
bacteria such as Pseudomonas aeruginosa.14
Quality by design (QbD) is a regulatory-based, modern 
quality-management system, focusing on the design phase 
of the development of new pharmaceutical products.15 The 
concepts behind QbD were introduced in international 
guidelines developed for the pharmaceutical industry. 
These include the International Council for Harmonisation 
of Technical Requirements for Pharmaceuticals for Human 
Use Q8(R2), Q9, and Q10 guidelines16–18 that describe the 
steps and elements of the QbD concept. Nowadays, the 
application of this quality-management methodology is 
strongly recommended by regulatory authorities such as the 
European Medicines Agency and the US Food and Drug 
Administration. QbD is a risk-based approach with risk 
assessment (RA) being its most important element. The RA 
process is capable of identifying the factors that have the 
highest influence on the quality of a final drug product; these 
critical factors can be ranked and a theoretical prediction 
about their effects/significance is made. Applying this 
approach can reduce the time required for drug develop-
ment in practice and it also contributes to a more effective 
allocation of human and financial resources.19 Once new 
pharmaceutical developments are designed by using the QbD 
methodology, the investigations in practice can be optimized 
and their effectivity is increased.
The technological aspects of preparing a DPI may 
follow two possible ways. On the one hand, the conven-
tional, carrier-based formulation method utilizes macrosize 
lactose with microparticles of the active agent bound to its 
surface. On the other hand, the effective and modern way 
of formulation is a carrier-free technology where a special 
co-formulation containing the active agent plus additives 
is applied and a microsized final product with a narrow 
particle size range (2–4 μm) and low density (,1 g⋅cm-3) 
is produced.20 The importance of carrier-free systems lies 
in their improved aerodynamical properties, resulting in a 
highly concentrated drug deposition in the alveolar regions.21 
When green technology is applied for drug formulation, 
chemical products and processes are designed, manufac-
tured, and disposed with reduced environmental pollution 
risk and a lower burden of hazardous substances.22 A spray-
drying procedure is frequently applied as the method for 
particle formulation.23 Using ethanol as co-solvent can help 
to produce micronized systems. However, the presence of 
excipients is also a crucial factor in terms of modifying the 
surface and stabilizing particle size. Belotti et al concluded 
that the highest lung deposition was reached upon applying 
a maximum of 10% of ethanol beside the excipients.24
So far few inhaled antibiotics have been approved or have 
entered the late stages of clinical development.25 Therefore, 
the goal of our study was to design a DPI of ciprofloxacin 
hydrochloride (CIP) in the form of a carrier-free system by 
applying green technology. The QbD approach in the design 
phase helps in focusing on connections and effects among 
the material characteristics, selected production process, 
investigation methods, and final product properties. The 
practical product development was performed after the QbD-
based RA and theoretical prediction. Microparticles of CIP 
containing different excipients in optimal concentrations 
were prepared. The effects of different excipients on the 
micrometric and aerosolization properties as well as struc-
tural characteristics of the DPI products were investigated.
Materials and methods
Materials
CIP, a fluoroquinolone-type antibiotic was kindly supplied 
by Teva Pharmaceutical Works Ltd. (Debrecen, Hungary). 
Polyvinyl alcohol 3-88 (PVA), a water-soluble synthetic 
polymer was purchased from BASF (Cologne, Germany). 
The amino acid l-leucine (LEU) was obtained from 
Hungaropharma Ltd. (Budapest, Hungary). Hydroxypropyl-
beta-cyclodextrin (CD), a cyclic oligosaccharide was donated 
by Cyclolab Ltd. (Budapest, Hungary).
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Methods
QbD methodology in formulation design
As part of the QbD methodology, knowledge space devel-
opment and RA were performed. To illustrate the relevant 
knowledge and information, an Ishikawa diagram was 
set up. The technical tool used for the RA was LeanQbD® 
software (QbDWorks LLC, Fremont, CA, USA). In the first 
step, the desired product was defined and the elements of the 
quality target product profile (QTPP) were determined. Next, 
the critical quality attributes (CQAs) and the critical process 
parameters (CPPs) of the selected production method were 
identified. CQAs have critical influence on the quality charac-
teristics of the final product and CPPs critically influence the 
CQAs and QTPPs. In the following step an interdependence 
rating was performed among the QTPPs and CQAs, and 
also among the CQAs and CPPs and was categorized on a 
three-level scale. The interaction between the elements was 
described as “high” (H), “medium,” (M) or “low” (L). Its 
dynamism is presented in figures generated by the software. 
This was followed by the probability rating step where CPPs 
were estimated and categorized on a 10-point scale. Finally, 
Pareto charts were generated, presenting the numeric data 
and the ranking of each CQA and CPP.
Preparation of the microparticulate systems
As a preliminary investigation, solubility tests of CIP were 
carried out at 25°C either in a buffer solution (pH =7.4) or 
in distilled water (pH =4.4). Solubility was measured by 
ultraviolet/visible spectroscopy (UV/VIS) spectrophotometry 
(ATI-UNICAM UV/VIS spectrophotometer, Cambridge, 
UK). The concentration was determined 24 h after filtering 
the saturated system.
The significant solubility of CIP in distilled water allows 
its use as the solvent for spray-drying feed solution. Using 10% 
of ethanol in an aqueous solution is known to decrease the par-
ticle size because of its fast evaporation during spray drying.24 
Therefore, the feed solution was prepared by dissolving 1 gram 
of CIP plus different excipients at different concentrations in 
an aqueous solution containing 10% of ethanol. According 
to our previous research on the effects of organic solvent and 
additives on the habit (size and morphology) and aerosoliza-
tion characteristics of DPI systems,26 the optimal excipient 
concentration is achieved as shown in Table 1.
Spray drying is a one-step process through which it is 
possible to engineer and produce particles directly from solu-
tions with a controlled technique. Hence, spray drying was 
considered to be the appropriate technique to produce a dry 
powder for inhalation. The spray-drying process was carried 
out using a Büchi Mini Dryer B-191 (BÜCHI Labortechnik, 
Flawil, Switzerland); the parameters were optimized as 
shown in Table 2.26 The amount of dry powder yielded was 
determined between 65% and 70%. Generally during the 
spray-drying procedure nearly 30% of the sample could be 
lost. So our produced yield correlated with the normal sample 
production’s habit.
Particle size analysis
Particle size distributions of the spray-dried powders were 
determined by laser scattering using Malvern (Malvern 
Mastersizer Scirocco 2000; Malvern Instruments Ltd., 
Worcestershire, UK). Air was used as the dispersion medium 
for the microparticles from the entrance to the sample cell. 
Approximately 500 mg of product was loaded into the 
feeder tray. The particle size distribution was characterized 
by the D(0.1), D(0.5), and D(0.9) values and the specific 
surface area.
scanning electron microscopy
The morphology of CIP microparticles was investigated 
by scanning electron microscopy (Hitachi S4700; Hitachi 
Scientific Ltd., Tokyo, Japan) at 10 kV. The samples were 
gold-palladium coated (90 s) with a sputter coater (Bio-Rad 
SC 502; VG Microtech, Uckfield, UK) using an electric 
potential of 2.0 kV at 10 mA for 10 min. The air pressure 
was 1.3–13.0 mPa.
Fourier-transform infrared spectroscopy
Fourier-transform infrared spectroscopy (FT-IR) spectra 
were recorded with an FT-IR spectrometer (Thermo Nicolet 
Table 1 composition of the DPi products containing an optimal 
concentration of excipients
No CIP (g) LEU (g) PVA (g) CD (g) Solvent (mL)
1 1 – – – 50
2 1 – 0.2 – 50
3 1 – – 0.9 50
4 1 0.4 – – 50
5 1 0.4 0.2 0.9 50
Abbreviations: DPI, dry powder inhalation; PVA, polyvinyl alcohol; CIP, ciproflox­
acin hydrochloride; leU, l-leucine; cD, cyclodextrin.
Table 2 Büchi Mini Dryer B-191 parameters for spray-drying 
procedure
Inlet 
temperature 
(°C)
Outlet 
temperature 
(°C)
Feed rate 
(mL⋅min-1)
Aspiration 
air (L⋅h-1)
Aspiration 
rate 
(L⋅min-1)
130 75 5 600 0.065
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AVATAR 330; LabX Midland, ON, Canada) between 
4,000 and 400 cm-1, at an optical resolution of 4 cm-1. The 
sample was mixed with 150 mg of dry KBr in an agate mortar 
and the mixture was pressed to obtain self-supporting disks 
at 10 tons.
X-ray powder diffraction
The crystal structure of spray-dried powders including dif-
ferent excipients were characterized using an X-ray powder 
diffraction (XRPD) BRUKER D8 Advance X-ray diffrac-
tometer (Bruker AXS GmbH, Karlsruhe, Germany). The 
powder samples were loaded in contact with a plane quartz 
glass sample slide with an etched square and measured with 
a slit-detector Cu Ni radiation source. Settings were as fol-
lows: voltage, 40 kV; current, 40 mA; time constant, 0.1 s; 
angular step 0.010°.
Differential scanning calorimetry
The thermal response of each product was measured using 
a differential scanning calorimeter (Mettler Toledo TG 821e 
DSC Mettler Inc., Schwerzenbach, Switzerland). About 
3–5 mg of powder was precisely weighed into differen-
tial scanning calorimetry (DSC) sample pans which were 
hermetically sealed and lid pierced. Each sample was on 
equilibrate for 10 min at ambient temperature before being 
heated to 400°C at a rate of 5°C⋅min-1. Data analysis was 
performed using the STARe software (Mettler Toledo Mettler 
Inc., Schwerzenbach, Switzerland).
aerodynamic particle size analysis
Aerodynamic particle size distribution was determined using 
a seven-stage Anderson Cascade Impactor (Copley Scientific 
Ltd., Nottingham, UK). The flow rate was set to 60 L⋅min-1.
During the process, the aerosol moved along seven size 
stages according to the diameter of the particles and was 
then washed by methanol/phosphate buffer (60/40 v/v %) 
to collect the deposited drug. All samples were investigated 
by UV/VIS spectrometry at 271 nm.
The fine particle fraction (FPF) was established as the 
number of particles deposited at stage 2 and lower (#5 μm), 
divided by the total initial amount of the particles filled 
in the inhaler (10 mg). The mass median aerodynamic 
diameter (MMAD) was defined based on the graph as the 
particle size at which the line crossed the 50th percentile, 
indicating the particle diameter at which 50% of the aero-
sol particles by mass are larger and 50% are smaller.27 
Drug-emitted dose (ED), defined as the percentage of 
CIP exiting the DPI, was determined by subtracting the 
amount of CIP remaining in the DPI from the initial mass 
of CIP loaded. To determine the drug content, 10 mg of the 
ciprofloxacin-bearing spray-dried microparticles was dis-
solved in methanol/phosphate buffer (60/40) and analyzed 
by UV spectroscopy.
Dissolution test: ciP release from the microparticles 
at ph 7.4
To check the difference in drug release between the prepared 
products, 10 mL of phosphate buffer (pH 7.4, as the pH in 
the lung) was used to suspend an equivalent of 50 mg of CIP 
content in all products. After 1, 2, 3, 4, and 5 min, sample 
was taken out, filtered, and the concentration measured by 
UV spectroscopy at a maximum wavelength of 271 nm.
Results and discussion
Formulation design by the QbD approach
The first step was setting up an Ishikawa (fishbone) diagram 
including all the parameters influencing the desired DPI 
product containing CIP as the active agent. The parameters 
were ranked into four groups (Figure 1), namely 1) material 
characteristics, 2) production method, 3) test methods, and 
4) product characteristics. This process served as a preliminary 
knowledge and information collection, which can help in the 
designing of the experiments and the selection of the CQAs 
and CPPs of the drug development procedure.
The next step was the selection of the QTPPs, CQAs, 
and CPPs for the aimed DPI product. Table 3 lists these 
with their selected targets and their justification, along with 
the explanations for the classification of the factors selected 
in each groups.
Figure 2 shows the elements and results of the QbD-
based RA. Figure 2A presents the interdependence rating 
of the QTPPs and CQAs, and of the CQAs and CPPs. Each 
interaction was ranked as high (H), medium (M), or low (L). 
The same three-level scale was used for the occurrence 
rating of the CPPs, which is presented in Figure 2B. These 
interdependence and occurrence ratings were followed by 
risk estimation calculations using the RA software, which 
produced a precise impact score (or severity score) for each 
critical influencing parameter. The calculated and ranked 
severity scores for the CQAs and CPPs are presented in 
Pareto charts (Figure 2C) generated by the software. Pareto 
charts also give a graphical overview of the hierarchy of 
CQAs and CPPs based on their calculated numerical differ-
ence in their influence on the aimed quality of the product. 
In this special case the particle size (or the specific surface 
area) of the API is the CQA to have the highest impact on the 
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quality of the aimed final product. It is followed by wettability 
and dissolution properties. The next ones are appearance 
and the excipients’ profile, while primer solubility and the 
structure of the API are found to have the lowest impact. 
The impact of “particle size and SSA” is 41.6% higher than 
that of “wettability” and is 47.8% and 78.9% higher than the 
impact of “dissolution” and “appearance”, respectively. 
Comparing “structure” and “particle size”, the difference in 
their impact on the quality of the final product is 183% for 
“particle size”. Among the CPPs product, “composition” 
was found to have the highest impact on the desired final 
product’s quality. It is followed by the “outlet temperature”, 
then “inlet temperature”, and “feed rate”. The impact of the 
“composition on product quality” is 29% higher than that 
of “temperature”. Nevertheless, there is a 34% difference 
between the critical process factor with the highest effect 
(composition) and the lowest effect (feed rate) on the final 
product’s properties.
These results of the software-based RA highlight those 
factors that need the highest attention during the practical 
development phase when we decide about the exact composi-
tion and select the materials and excipients, etc.
Micrometric properties
Particle size analysis
Since all the powders were prepared under similar drying 
conditions, in the spray-drying process the final particle size 
distributions of the samples were comparable. The smallest 
particle size was measured for the DPI of CIP containing 
PVA, while the largest value was measured for the DPI of 
CIP containing PVA, LEU, and CD as excipients. This size 
interval is optimal for lung deposition, so a local treatment 
of the respiratory tract can be achieved by any of the com-
positions tested.
Microparticulate DPIs had a narrow particle size distri-
bution which is highly advantageous for pulmonary DPI, 
because it enables the particles to potently target a specific 
lung region. In consequence, it enables a high deposition 
of drug particles. Results of the particle size analysis are 
shown in Table 4.
Particle size morphology
Field-emission scanning electron micrographs of the spray-
dried microparticles are shown in Figure 3. The DPI of 
CIP containing PVA has a relatively smooth surface with 
Figure 1 Ishikawa diagram illustrating the parameters influencing the quality of the ciprofloxacin­containing DPI product.
Abbreviations: DPI, dry powder inhalation; FPF, fine particle fraction; MMAD, mass median aerodynamic diameter; LEU, l-leucine; FT-ir, Fourier-transform infrared 
spectroscopy; PVa, polyvinyl alcohol.
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spherical geometry in contrast to the DPI of CIP containing 
LEU which was found to be cavitated. Such deep cavities 
can also be observed in the DPI containing cyclodextrin, 
but those cavities are less deep than those in the DPI of CIP 
containing LEU. The DPI of CIP containing PVA, LEU, and 
CD contains no cavities, which may result from the dominant 
effect of PVA to produce smooth surfaces.
structural characteristics
Differential scanning calorimetry
A sample containing only raw CIP was prepared by the same 
method to serve as a control. The thermal response of CIP 
alone had a broad diffuse endothermic peak at about 145°C 
indicative of recrystallization and a sharp endothermic peak 
at 312°C indicative of melting.
Table 3 Selected QTPPs, CQAs, and CPPs of a ciprofloxacin­containing DPI formula, their target, justification, and explanation
Target Justification/explanation
QTPPs
Therapeutic 
indication
antibiotic
(respiratory tract 
infections)
Antibacterial therapy is essential in respiratory tract infections. Ciprofloxacin is a second­
generation fluoroquinolone antibiotic with a broad spectrum of activity. It is especially effective 
against infections caused by gram-negative bacteria
Target patient 
population
adults Literature data support a wide use of fluoroquinolone antibiotics in adults. It is a pregnancy 
category c antibiotic, considered to be safe during breastfeeding. it is also allowed for pediatric 
therapy but is never a first­line choice
Target patient group, as QTPP affects the dose selection and the route of administration
route of 
administration
Pulmonary administration a relatively new route of administration for local antibacterial therapy. Pulmonary application 
avoids the first­pass effect and reduces systemic exposure and the risk of side effects
site of activity local effect Producing a local effect in pulmonary infections allows dose reduction of the antibiotics, 
associated with a lower risk of side effects
Preselection of the desired site of activity as QTPP affects the aPi used, as well as the dose and 
the dosage form selected
Dosage form Dry powder for 
pulmonary use
Dry powders with a particle size of 2–4 μm are required for the optimal deposition in lungs
Predetermination of the adequate dosage form is a QTPP according to the ich Q8 guideline
Dissolution profile increased dissolution Dissolution profile is a recommended QTPP as it affects the bioavailability and pharmacokinetics 
and is critically related to the quality, safety, and efficacy of the medicinal product
CQAs
excipients (quality 
profile)
excipients assure proper 
quality characteristics 
by modifying the 
size, morphology, 
hydrophilicity, and stability 
of the DPi product
Polyvinyl alcohol 3­88 is a microfine coating material
The amino acid l-leucine can be well co-spray-dried with certain active compounds to modify 
the drug’s aerolization behavior
Dimethyl-beta cyclodextrin can be applied as a drug distribution enhancer
As CQAs, excipients are critically related to the dissolution and quality profile of the final 
product
Particle size/specific 
surface area (ssa)
homogeneous, 
microsized product  
of 2–4 μm
Microsize dimension has the optimal specific surface area and optimal administration properties 
for pulmonary use
size is critically related to pulmonary administration and to its local and/or systemic therapeutic 
effect, thereby to product safety, efficacy, and quality
appearance Microparticle Microparticle formulation is suitable to achieve an increased ssa, an improved wettability, and a 
high amount of dissolved drug
It is critically related to efficacy
Dissolution improved dissolution rate 
(100% in 5 min)
The dissolution profile highly affects the therapeutic effect. Accelerated drug release induces an 
immediate local effect. It is related to the modification of the SSA, wettability, and solubility
Wettability hydrophyl product Wettability is critical for the drug’s adhesion the pulmonary mucosa. it is critically related to 
efficacy
structure (crystalline/
amorphous)
stable form
(crystalline/amorphous)
The crystalline or the amorphous state of the aPi affects stability and release properties. it is 
critically related to efficacy and quality
solubility Water-soluble Solubility has a remarkable influence on the bioavailability of the drug/product
CPPs
composition
(co-spray drying)
Micronized size, stabilized 
structure using additives
Additives contribute to reaching the desired and predefined quality of the final co­spray­dried 
product
inlet temperature
(co-spray drying)
130°c Inlet temperature has a critical influence on optimal drying and thus influences the final 
product’s appearance
Outlet temperature
(co-spray drying)
75°c Outlet temperature has a critical influence on optimal drying of the desired co­spray­dried 
final product
Feed rate
(co-spray drying)
5 ml⋅min-1 Feed rate has a critical influence on the formation of co­micronized particles
Abbreviations: QTPPs, quality target product profiles; CQAs, critical quality attributes; CPPs, critical process parameters; DPI, dry powder inhalation. 
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Figure 2 results of (A) the interdependence rating of the QTPPs and cQas and of the cPPs and cQas, (B) the occurrence rating of the cPPs, and (C) Pareto charts of 
the cQas and cPPs with calculated numeric severity scores generated by the ra software.
Abbreviations: QTPPs, quality target product profiles; CQAs, critical quality attributes; CPPs, critical process parameters; RA, risk assessment.
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Table 4 Particle size of the microparticles of various composi-
tions prepared
Material D(0.1)  
µm
D(0.5)  
µm
D(0.9)  
µm
Specific surface 
area (m2⋅g-1)
ciP_sPD 1.31±0.01 2.44±0.02 4.44±0.01 2.76±0.03
ciP_PVa_sPD 1.22±0.04 2.38±0.03 4.57±0.03 2.85±0.02
ciP_cD_sPD 1.68±0.03 3.02±0.06 5.24±0.04 2.20±0.09
ciP_leU_sPD 1.62±0.05 2.84±0.02 4.84±0.00 2.33±0.01
ciP_PVa_ 
cD_leU_sPD
1.58±0.06 3.27±0.01 6.42±0.02 2.14±0.02
Abbreviations: PVA, polyvinyl alcohol; CIP, ciprofloxacin hydrochloride; 
leU, l-leucine; cD, cyclodextrin; sPD, spray drying.
In the thermograms of microparticles containing CIP 
and PVA, characteristic endothermic peaks were detected. 
There were two exothermic peaks at 152°C and 190°C due 
to recrystallization during spray drying, and a sharp endo-
thermic peak was detected at 312°C indicative of melting. 
Interestingly, the microparticles containing CD were shown 
to have a lower melting point at 207°C due to their amorphous 
structure resulting from spray drying. The microparticles 
containing LEU were shown to have two different endo-
thermic peaks at 270°C and 308°C indicating the melting 
&,3B63'N9 PP îN 6(8 P&,3B5$:N9 PPîN 6(8 P
&,3B39$B&'B/(8B63'N9 PP îN 6(8 P&,3B/(8B63'N9 PP îN 6(8 P
&,3B39$B63'N9 PP îN 6(8 P&,3B&'B63'N9 PP îN 6(8 P
Figure 3 scanning electron micrographs of the spray-dried microparticles.
Abbreviations: CIP, ciprofloxacin hydrochloride; SPD, spray drying; RAW, unattended material; CD, cyclodextrin; LEU, l-leucine; PVa, polyvinyl alcohol.
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points of LEU and CIP, respectively. Figure 4 shows the DSC 
thermograms of raw CIP and of the different CIP-containing 
microparticles investigated.
X-ray powder diffraction
The XRPD diffractogram of raw CIP shows many character-
istic peaks indicating a high degree of crystallinity, but the 
peak with the highest intensity is at 9.09° 2θ area.
Since the spray-drying parameters were similar for all 
the formulations, the differences in crystallinity must be 
attributable to the presence of the different excipients. The 
spray-dried products containing excipients exhibit a large 
degree of amorphicity and a very low degree of crystal-
linity. The only product that shows significant crystallin-
ity is the DPI of CIP containing LEU, suggesting that the 
co-spray-dried formulation is composed of crystalline LEU 
and amorphous CIP. Formulations containing CD have a 
completely amorphous character. The characteristic peaks 
of spray-dried microparticles at 6 2-Theta degree show the 
tendency of CIP to recrystallize from its polymorph. The 
XRPD diffractograms of raw CIP and of the microparticle 
compositions investigated are seen in Figure 5.
Fourier-transform infrared spectroscopy
The FT-IR spectrum revealed that raw CIP exhibits a peak 
at 1,707 cm-1 as a consequence of the cyclic C=O stretch-
ing that induces a shift toward the higher wave numbers 
due to the association with the OH groups of other com-
ponents. The magnitude of the shift in the C=O stretching 
for the bounded dimer form is inversely proportional to the 
strength of the interaction between CIP and the excipients. 
Figure 4 Thermograms of raw ciP and of the different ciP-containing microparticles investigated.
Abbreviations: CIP, ciprofloxacin hydrochloride; SPD, spray drying; RAW, unattended material; CD, cyclodextrin; LEU, l-leucine; PVa, polyvinyl alcohol.

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The other feature detectable at the FT-IR spectrum is the 
widening of the C=O stretching bond, caused by the configu-
ration of the hydrogen realignment between the excipients 
and the C=O bond of ciprofloxacin. The shift of the above 
bond indicates that the interaction between CIP and LEU or 
PVA is weaker than that between CIP and CD. The bands 
assigned to N-H in the FT-IR spectrum are seen at 1,612 cm-1. 
For the microparticles containing excipients, several peaks 
are missing. The peaks at 987 cm-1 have completely disap-
peared in all cases due to the change from the dimeric to the 
monomeric state. The bands assigned to N-H in the FT-IR 
spectrum can be seen at 1,612 cm-1 both in the raw CIP and in 
the spray-dried microparticle compositions. Figure 6 shows 
the FT-IR spectra of the raw material and the microparticle 
compositions investigated.
in vitro characteristics
aerodynamic particle size analysis
Generally, the single spray-dried CIP formulation had a 
low aerosol performance (FPF =31.68±1.43). In contrast, 
the combined spray-dried formulations containing CIP plus 
excipients exhibited a significantly improved aerosol per-
formance. While even the presence of PVA or CD raised 
the FPF value of the microparticles, those containing LEU 
were characterized by the highest aerosol performance. 
These results show that the use of excipients can signifi-
cantly improve the aerodynamic behavior of CIP-containing 
microparticles. LEU has the highest potential to improve the 
aerosol performance (FPF =80.27%±1.65%). This value indi-
cates that more than 80% of the particles delivered from the 
inhaler have a volume aerodynamic diameter less than 5 μm. 
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Figure 5 XrPD diffractograms of raw ciP and of the ciP-containing microparticle 
compositions investigated.
Abbreviations: XRPD, X­ray powder diffraction; CIP, ciprofloxacin hydrochloride; 
sPD, spray drying; raW, unattended material; cD, cyclodextrin; leU, l-leucine; 
PVa, polyvinyl alcohol.
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Figure 6 (Continued)
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Drug contents, FPF, median aerodynamic diameter, and ED 
values are shown in Table 5.
Dissolution test
Solubility test as a preliminary experiment was carried out. 
Table 6 shows the solubility of CIP. In accordance with lit-
erature data, our measurements confirmed that the increase 
in pH decreases the solubility of CIP.28
Dissolution tests focused on free CIP release. Figure 7 
shows ciprofloxacin release from the microparticles at pH 7.4. 
A slower rate of CIP release was observed for the spray-dried 
microparticles containing PVA compared to those without 
PVA. This behavior can be interpreted by the controlled 
release induced by PVA. Drug release was shown to rise 
substantially in the presence of LEU and CD, and micropar-
ticles containing LEU as the only excipient were shown to 
be characterized by the highest rate of CIP release, with full 
API release within 3 min.
Conclusion
Pulmonary infections are highly common and often 
recurrent. A possible therapeutic approach is to deliver 
antibiotics directly to the site of the infection in order to 
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Figure 6 FT­IR spectra of ciprofloxacin hydrochloride (CIP) and the CIP­containing microparticle compositions investigated.
Abbreviations: FT-ir, Fourier-transform infrared spectroscopy; sPD, spray drying; raW, unattended material; cD, cyclodextrin; leU, l-leucine; PVa, polyvinyl alcohol.
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Table 5 Drug content, fine particle fraction (FPF), mass median 
aerodynamic diameter (MMaD), and emitted dose (eD) of the 
ciP-containing microparticle compositions investigated
DPI Drug  
content (%)
FPF (%) MMAD  
(µm)
ED (%)
ciP_sPD 100±0 31.68±1.4 7.23±0.01 99.95±0.5
ciP_PVa_sPD 85±0.07 60.18±1.3 3.61±0.05 95.92±0.4
ciP_cD_sPD 59±0.03 58.54±1.1 3.19±0.01 96.93±0.5
ciP_leU_sPD 72±0.08 80.27±1.7 2.15±0.08 95.81±0.6
ciP_PVa_ 
cD_leU_sPD
45±0.24 45.93±1.4 4.53±0.02 97.68±0.4
Abbreviations: PVA, polyvinyl alcohol; CIP, ciprofloxacin hydrochloride; LEU, 
l-leucine; cD, cyclodextrin; sPD, spray drying.
Table 6 Maximum measured concentration of ciprofloxacin 
hydrochloride filtered saturated solution
Solvent pH Concentration
(mg⋅mL-1)
λ max
(nm)
Buffer solution 7.4 6.3 271
Distilled water 4.4 41.9 275
increase local (effective) drug concentration and decrease 
the chance of adverse effects. In this study microparticles of 
CIP hydrochloride for DPI were prepared by spray-drying 
technology, applying predefined optimal drug formulation 
parameters.
The QbD-based formulation design helped to synthesize 
the relevant knowledge both from the literature and from 
previous experience, using modern quality-management 
tools. The QbD methodology and the RA tools were able 
to select the critical factors (CQAs and CPPs) that have the 
highest influence on the dedicated DPI production procedure, 
and thus on the quality of the final DPI product. The critical 
factors were not only identified but also ranked and priori-
tized according to their calculated precise severity (impact) 
scores. It has been established that the particle size of the 
API, the wettability and dissolution characteristics, as well 
as the composition of the DPI product are to be focused on 
during the practical development phase. The different DPI 
formulations were prepared according to these preliminary 
parameter rankings and priority classifying. After the sub-
sequent development in practice it should be determined 
whether all the particles produced are in acceptable particle 
size for optimal deposition in the lungs.
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Using PVA as an excipient for the CIP-containing DPI 
was shown to decrease the size of the microparticles signifi-
cantly. The application of LEU to the microparticles induced 
a significant improvement in the FPF and in the aerodynamic 
behavior, and also allows a very fast drug release. Besides 
the adequate formula development, this study confirmed 
that the QbD-guided modern research methodology could 
be properly used in the early development phase of innova-
tive formulations like DPIs and resulted in a risk-based and 
effective product development. In addition, applying QbD in 
such studies could help to avoid profitless efforts in further 
phases of the development process.
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